Account
Case Studies
02.04.2024
Securing the optimum launch price for a novel phar...

Looking to enhance your market access capabilities? Remap Consulting are the partner to help you lau...

Read more
News
13.02.2024
World EPA Congress 2024

The World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar...

Read more
Articles
08.02.2024
Is the attractiveness of launch in the UK changing...

This expert article focusses on the new proportionate approach, and the international recognition pr...

Read more
News
16.11.2023
ISPOR Europe 2023

We're thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We'll...

Read more
Articles
01.11.2023
World Orphan Drug Congress Europe 2023 REPORT

We summarise the World Orphan Drug Congress Europe 2023 including keynote and panel sessions on EU H...

Read more
Webinar
31.10.2023
NICE’s Proportionate Approach to Technology ...

Webinar: Our experts discuss NICE's proportionate approach to technology appraisals and the implicat...

Read more
Publications
25.10.2023
ISPOR Europe 2023: Can Just Three PICOs be Feasibl...

This research aims to understand if just three PICOs are feasible by analysing recent HTA assessment...

Read more
Publications
25.10.2023
ISPOR Europe 2023: How Aware Are Biotech and Pharm...

Our research aims to gauge awareness of the new EU HTA process within the pharmaceutical industry in...

Read more
Publications
25.10.2023
ISPOR Europe 2023: How Has NICE’s Severity M...

Our study aims to understand how the severity modifier has been implemented so far and its impact on...

Read more
Articles
11.10.2023
Unlocking the Potential of Cell and Gene Therapy: ...

We outline the challenges pharma companies encounter when launching cell and gene therapies, and ass...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.